64.01

0.91% 0.58

Cytokinetics Inc (CYTK)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Cytokinetics Inc stock is traded at $64.01, with a volume of 677.52K. It is up +0.91% in the last 24 hours and down -7.65% over the past month. Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Previous Close:

$63.43

Open:

$64.81

24h Volume:

677.52K

Relative Volume:

0.30

Market Cap:

$8.90B

Revenue:

$105.82M

Net Income/Loss:

$-829.61M

P/E Ratio:

-9.3542

EPS:

-6.8429

Net Cash Flow:

$-548.92M

1W Performance:

+3.23%

1M Performance:

-7.65%

6M Performance:

-2.08%

1Y Performance:

+1.93%

1-Day Range:

$63.86

$65.57

1-Week Range:

$60.99

$64.01

52-Week Range:

$54.30

$88.31

Cytokinetics Inc Stock (CYTK) Company Profile

Name

Cytokinetics Inc

Sector

Healthcare (1051)

Industry

Biotechnology (593)

Phone

(650) 624-3000

Address

350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA

Employee

673

Twitter

@Cytokinetics

Next Earnings Date

2026-11-04

Latest SEC Filings

CYTK's Discussions on Twitter

Compare CYTK vs VRTX, MRNA, REGN, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CYTK Cytokinetics Inc	64.01	8.90B	105.82M	-829.61M	-548.92M	-6.8429
VRTX Vertex Pharmaceuticals Inc	509.72	129.19B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	237.78	94.93B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	801.11	82.48B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	848.35	53.35B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	371.37	42.01B	5.76B	514.49M	1.10B	4.4813

Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-29-26	Upgrade	UBS	Neutral → Buy
May-19-26	Initiated	Citigroup	Buy
Apr-10-26	Initiated	Wells Fargo	Overweight
Jan-28-26	Resumed	Barclays	Overweight
Dec-18-25	Upgrade	Goldman	Neutral → Buy
Jul-30-25	Resumed	Raymond James	Mkt Perform
Apr-24-25	Initiated	Barclays	Overweight
Feb-07-25	Initiated	Citigroup	Buy
Jan-22-25	Initiated	Stifel	Buy
Nov-08-24	Initiated	RBC Capital Mkts	Outperform
Aug-13-24	Downgrade	Goldman	Buy → Neutral
Jan-24-24	Downgrade	UBS	Buy → Neutral
Jan-05-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-09-23	Initiated	Goldman	Buy
Nov-07-23	Initiated	B. Riley Securities	Buy
Aug-15-23	Initiated	SVB Securities	Outperform
Feb-17-23	Initiated	BofA Securities	Neutral
Dec-23-22	Reiterated	Needham	Buy
Dec-20-22	Initiated	Truist	Buy
Oct-11-22	Initiated	UBS	Buy
Jan-28-22	Initiated	Goldman	Buy
Dec-22-21	Initiated	Oppenheimer	Outperform
Dec-10-21	Initiated	JP Morgan	Overweight
Oct-07-21	Initiated	Jefferies	Buy
Mar-12-21	Initiated	Wolfe Research	Outperform
Feb-18-21	Initiated	Barclays	Overweight
Jan-20-21	Reiterated	H.C. Wainwright	Buy
Oct-29-20	Initiated	Goldman	Neutral
Jul-10-20	Initiated	Raymond James	Strong Buy
May-05-20	Initiated	Mizuho	Buy
Apr-09-20	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Sep-21-18	Initiated	Cantor Fitzgerald	Overweight
Sep-10-18	Resumed	Morgan Stanley	Equal-Weight
Nov-22-17	Reiterated	Morgan Stanley	Overweight
Nov-22-17	Downgrade	Needham	Strong Buy → Buy
Nov-21-17	Reiterated	H.C. Wainwright	Buy
Jul-31-17	Initiated	Morgan Stanley	Overweight
Mar-08-17	Initiated	Rodman & Renshaw	Buy
Feb-06-17	Upgrade	Needham	Buy → Strong Buy
Dec-16-16	Initiated	Cantor Fitzgerald	Overweight
Jul-28-16	Reiterated	Needham	Buy
Nov-10-15	Reiterated	FBR Capital	Outperform
Nov-09-15	Reiterated	ROTH Capital	Buy
Jul-24-15	Reiterated	MLV & Co	Buy
Dec-31-14	Reiterated	ROTH Capital	Buy
Nov-04-14	Upgrade	MLV & Co	Hold → Buy
Apr-28-14	Reiterated	Needham	Buy

View All

Cytokinetics Inc Stock (CYTK) Latest News

11:24 AM

Cytokinetics Sees Myqorzo Launch Strength Carry Into 2027, RBC Says - marketscreener.com

11:24 AM

Oct 14, 2026

UBS cuts Cytokinetics stock price target on valuation, keeps Buy - Investing.com

Oct 14, 2026

Oct 13, 2026

Cytokinetics Insider Sold Shares Worth $471,600, According to a Recent SEC Filing - Yahoo Finance

Oct 13, 2026

A $1.42M proposed share sale at Cytokinetics (CYTK) draws on Robert Blum’s stock options. - Stock Titan

Oct 13, 2026

Cytokinetics (CYTK), What Is Behind The Fresh Attention? - Yahoo Finance

Oct 13, 2026

Oct 12, 2026

Cytokinetics (CYTK) Stock Looks Hard To Pin Down Following Strong Heart Drug Updates - Yahoo Finance

Oct 12, 2026

Cytokinetics, Incorporated (CYTK) Stock Forecasts - Yahoo Finance

Oct 12, 2026

Cytokinetics presents additional aficamten data from trial - Investing.com

Oct 12, 2026

Serious heart failure events affected 4.7% taking aficamten, versus 1.2% on placebo. - Stock Titan

Oct 12, 2026

Cytokinetics Q2 2026 Earnings Call: Complete Transcript - Benzinga

Oct 12, 2026

Oct 11, 2026

Cytokinetics EVP Fady Malik sells $214,830 in company stock - Investing.com

Oct 11, 2026

Form 4 Cytokinetics Inc For: 11 October By Investing.com - Investing.com Nigeria

Oct 11, 2026

Oct 08, 2026

Cytokinetics Falls as Investors Appear to Take Profits Despite Recent Aficamten Progress - Quiver Quantitative

Oct 05, 2026

Oct 04, 2026

CYTK6536068 Bond Profile: Coupon and Redemption - TradingView

Oct 04, 2026

Oct 03, 2026

Wells Fargo Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $105 - Moomoo

Oct 03, 2026

Cytokinetics, Incorporated (CYTK) Stock Forecasts - Yahoo! Finance Canada

Oct 03, 2026

Oct 02, 2026

Cytokinetics Inc. Advanced Charts | CYTK - Barron's

Oct 02, 2026

Cytokinetics Announces Four Presentations at HFSA 2026 Highlighting Aficamten Data in Hypertrophic Cardiomyopathy - Quiver Quantitative

Oct 02, 2026

Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026 - GlobeNewswire Inc.

Oct 02, 2026

Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026 - Yahoo Finance

Oct 02, 2026

Oct 01, 2026

CYTK4910847 Bond Profile: Coupon and Redemption - TradingView

Oct 01, 2026

Sep 30, 2026

Cytokinetics (CYTK) Launches ASPEN-HCM Study to Evaluate Myqorzo in Obstructive Hypertrophic Cardiomyopathy - gurufocus.com

Sep 30, 2026

Cytokinetics launches real-world study of heart drug MYQORZO - Investing.com

Sep 30, 2026

Cytokinetics launches real-world study of heart drug MYQORZO By Investing.com - Investing.com Canada

Sep 30, 2026

Cytokinetics Announces Start of ASPEN-HCM Real-World Study of MYQORZO in Symptomatic Obstructive HCM - Quiver Quantitative

Sep 30, 2026

Cytokinetics Launches Aspen-Hcm A Real-World Study Evaluating Myqorzo® (Aficamten) In Symptomatic Obstructive Hypertrophic Cardiomyopathy - TradingView

Sep 30, 2026

A new study aims to enroll about 400 adults to assess a heart drug in everyday care. - Stock Titan

Sep 30, 2026

Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy - Yahoo Finance

Sep 30, 2026

Sep 29, 2026

Equity in earnings of Cytokinetics, Incorporated – HAN:KK3A - TradingView

Sep 29, 2026

ETFs Investing in Cytokinetics, Incorporated Stocks - TradingView

Sep 29, 2026

Form 4 Cytokinetics Inc For: 29 September By Investing.com - Investing.com Nigeria

Sep 29, 2026

Form 4 Cytokinetics Inc For: 29 September By Investing.com - Investing.com South Africa

Sep 29, 2026

Cytokinetics CEO Robert Blum sells $490,949 in stock - Investing.com

Sep 29, 2026

Cytokinetics CEO Robert Blum sells $490,949 in stock By Investing.com - Investing.com Canada

Sep 29, 2026

Form 4 Cytokinetics Inc For: 29 September By Investing.com - Investing.com Canada

Sep 29, 2026

Sep 28, 2026

Cytokinetics Insider Sold Shares Worth $490,950, According to a Recent SEC Filing - moomoo.com

Sep 28, 2026

At $65.46 a share, Cytokinetics (CYTK) CEO Robert Blum sold 7,500 shares after exercising options. - Stock Titan

Sep 28, 2026

Weekly Recap: MYQORZO US/Germany uptake and COMET/AMBER program updates - TradingView

Sep 28, 2026

Sep 25, 2026

Cytokinetics Maps MYQORZO Expansion, Heart Failure Pipeline at Bernstein Conference - TradingView

Sep 25, 2026

Cytokinetics Maps MYQORZO Expansion, Heart Failure Pipeline at Bernstein Conference - Yahoo Finance

Sep 25, 2026

CYTK5615147 Bond Profile: Coupon and Redemption - tradingview.com

Sep 25, 2026

Sep 24, 2026

Cytokinetics, Incorporated (CYTK) Stock Forecasts - Yahoo! Finance Canada

Sep 24, 2026

Cytokinetics, Incorporated (CYTK) Stock forecasts - Yahoo Finance Singapore

Sep 24, 2026

Sep 23, 2026

Cytokinetics (CYTK): Can Myqorzo Growth Create a New Biopharma Success Story? - Yahoo Finance

Sep 23, 2026

Sep 22, 2026